AgileBiotics B.V. is a pharmaceutical company focusing on the discovery and development of novel antibiotcs for the treatment of multi-drug resistant infections.
AGILeBiotics is committed to contribute to the fight against bacterial resistance by bringing new therapeutic solutions to patients infected by multidrug resistant bacteria. Our vision is to accelerate the development of novel antibiotics by employing our technology OxaSelect on existing drugs, which are based on natural products, and give them a second life cycle on the antibiotic market.
AGILeBiotics is a spin-off company of the University of Groningen located in Groningen in the North of the Netherlands. The company is located in the InnoLab Chemie that offers state of the art laboratory facilities for start-up companies. All technologies AGILeBiotics is employing were co-invented and established at the University by the CEO of AGILeBiotics Dr. Andreas A. Bastian. Supported by the University of Groningen and the University Medical Center Groningen (UMCG), AGILeBiotics is developing its own drug pipeline of novel antibiotics to treat multidrug resistant infections.